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Alpha-Synuclein Is a Cellular Ferrireductase 
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Abstract 
a-synuclein (aS) is a cellular protein mostly known for the association of its aggregated forms with a variety of diseases that 
include Parkinson’s disease and Dementia with Lewy Bodies. While the role of aS in disease is well documented there is 
currently no agreement on the physiological function of the normal isoform of the protein. Here we provide strong 
evidence that aS is a cellular ferrireductase, responsible for reducing iron (III) to bio available iron (II). The recombinant form 
of the protein has a VMax of 2.72 nmols/min/mg and Km 23 mM. This activity is also evident in lysates from neuronal cell lines 
overexpressing aS. This activity is dependent on copper bound to aS as a cofactor and NADH as an electron donor. 
Overexpression of a-synuclein by cells significantly increases the percentage of iron (II) in cells. The common disease 
mutations associated with increased susceptibility to PD show differences in activity or iron (II) levels. This discovery may 
well provide new therapeutic targets for PD and Lewy body dementias. 
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Introduction 
The 140 residue presynaptic protein a-synuclein (aS) has been 
implicated in the pathogenesis of several neurodegenerative 
disorders including Parkinson’s disease (PD), Lewy body variant 
Alzheimer’s disease and dementia with Lewy bodies (DLB) [1]. 
The symptoms of these conditions result from a loss of 
dopaminergic neurons, primarily from the pars compacta region 
of the substantia nigra. This then leads to a disruption of activity in 
basal ganglia that govern movement. Accompanied with these 
symptoms is an accumulation of ubiquitin bound aS within 
diseased cells [2]. The precise mechanism by which this is related 
to cell death remains unknown. Furthermore, a key issue in the 
fight against Lewy body disorders is that the physiological function 
of aS remains unknown, although it is thought to be related to 
membrane binding [3]. 
It has previously been suggested that aS is a copper binding 
protein[4]. Other studies have revealed a potentially significant 
association with iron [5,6]. This factor may provide insight into its 
function as many proteins that bind redox active metals ions such 
as copper have a catalytic role. Previous investigations into the 
coordination of copper and iron binding to aS have failed to reach 
a consensus. Initial results showed aS to bind 5–10 molecules of 
copper [7,8] while a later study showed aS to bind copper at two 
high affinity sites with more copper able to bind at other lower 
affinity sites [4]. A more recent study found two, independent, 
non-interacting Copper (II) binding sites in the N-terminus of aS 
[9]. 
The function of aS has often been suggested to be associated 
with dopamine metabolism and a variety of data indicate changes 
to dopamine synthesis, storage and transport processes[10]. In 
particular, a number of studies have suggested that overexpression 
of aS alters the activity of the key enzyme involved in dopamine 
synthesis, tyrosine hydroxylase[11,12]. Dopamine synthesis in aS­
knockout mice is reduced.[13]. Parkinson’s disease shows changes 
to brain iron including the ratio of Fe(II) and Fe(III)[14]. Fe(II) is 
necessary for dopamine synthesis as it is a co-factor of tyrosine 
hydroxylase. Fe(III) may induce oxidative stress through interac­
tion with neuromelanin [15]. Therefore, regulation of the ratio of 
Fe(II) to Fe(III) might be important for the survival of 
dopaminergic neurons. However, all these suggestions are 
inferential and no direct observation of a function has been made 
so far. 
Our investigations of metal binding to aS lead us to investigate 
the potential of this interaction to endow function to the protein 
that might be relevant to the maintenance of Fe(II) levels in cells. 
Our findings demonstrate conclusively that aS is a ferrireductase. 
Results 
Metal Binding 
We first assessed the copper (II) and iron (III) binding to aS in  
order to gain insight into the significance of this association. 
Recombinant aS was cloned from human cell lines and expressed 
and purified by a method developed by our laboratory. 
Thermodynamic analysis using isothermal titration calorimetry 
(ITC) was used to assess the Cu(II) and Fe (III) binding dynamics 
of the protein. Figure 1 shows a representative isotherm for the 
delivery of glycine chelated copper (II) and unchelated iron (III) to 
aS. A titration of Fe (III) into Cu (II) loaded aS was also carried 
out. The isotherm for Copper (II) shows a net endothermic 
reaction as a result of the high enthalpy of copper disassociation 
from glycine. The overall effect of the glycine chelate on the 
isotherm was accounted for as previously described [16]. The 
fitting of a non-linear regression model (Microcal) to the data to 
the isotherm for Cu (II) revealed one binding site, with affinity of 
21log 9.43 M . The titration of iron (III) into aS produced an 
exothermic reaction suggesting two binding sites (Figure 1). The 
21affinity of Fe(III) for the protein was for log 5.02 M both sites. A 
titration of iron (III) into protein that has been allowed to 
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Figure 1. ITC analysis of copper and iron binding. ITC traces for titrations of Cu (II) or Fe (III) into 100 mM aS at pH  7, 25uC. An isotherm for the 
titration of Fe (III) into Cu (II) loaded protein is also shown (far right). 
doi:10.1371/journal.pone.0015814.g001 
equilibrate with 2 equivalents of copper produced an exothermic 
reaction. The reaction indicated two sites with a affinity of log 
214.50 M . Although the affinity at the sites was reduced the data 
indicated that aS can bind both copper and iron simultaneously. 
This then led us to hypothesise that copper loaded aS may be 
catalysing a redox process with the iron, perhaps reducing it to the 
ferrous form. 
Ferrireductase Activity in Recombinant Protein 
In order to assess whether aS displayed ferrireductase activity, 
we used recombinant protein for an assessment of precise enzyme 
kinetics. The copper (II) bound protein was subjected to a 
ferrozine ((3-(2-pyridyl)-5,6- bis(phenyl sulfonic acid)-1,2,4-tri­
azine), based assay to detect the reduction of iron (III) to iron 
(II), using NADH as an electron donor. Ferrozine forms a bis 
complex which is highly specific to the ferrous form of the ionic 
metal [17] and adsorbs light strongly at 562 nm. Figure 2(i) shows 
2+ a linear plot of standard Fe against absorbance for the 
determination of ferric iron concentrations. The ferric iron was 
added anaerobically as Fe (II) sulphate. For the assessment of aS 
ferrireductase activity Fe (III) was added as iron citrate. Controls 
in the absence of copper, protein or NADH were used to ensure 
any observed activity was due to the copper loaded protein. 
Figure 2(ii) shows the plot of the A562 against time for this 
experiment. For the copper loaded protein in the presence of 
NADH, concentrations of 20 mM and 30 mM Fe (III) citrate are 
shown. From the plot, it is clear that aS is able to catalyse the 
reduction of iron (III) to iron (II) in the presence of NADH and 
that this is dependent on the protein being loaded with copper (II). 
Increasing the concentration of substrate increases the rate of 
reaction in a predictable manner. Experiments were carried out 
with a range of substrate concentrations from 1 mM to 100 mM 
iron (III). Figure 2(iii) shows a plot of Vo against substrate 
concentration and figure 2(iv) shows a double reciprocal plot of 
this data. From these plots, the Vmax and Km can be calculated for 
the reaction (table 1). Certain gene mutations have been associated 
with an increased risk of PD [18] and as such these mutants were 
generated and tested to assess any affects on the ferrireductase 
activity of the protein. Figure 3 shows the double reciprocal plots 
for this data. From the plot, it is clear there is a small but 
significant affect on the activity of the protein. Table 1 summarises 
the key kinetic data obtained. We also analysed the homologue of 
aS, beta-synuclein (bS) but this protein had no activity in this assay 
(data not shown) suggesting the ferrireductase activity is specific to 
aS. 
aS Increases Cellular Ferriductase Activity and Fe(II) 
Levels 
With data obtained from recombinant protein, there is clearly a 
need to investigate whether cellular forms behave in a similar way. 
As such, we also transfected human neural cell lines with aS and 
its disease associated mutants to overexpress the protein in a cell 
culture based system. Lysates were then prepared and equal 
quantities of protein, assessed by Bradford assay and western blot, 
were assayed under identical conditions to those before. Figure 4(i) 
shows a plot of the A562 against time for the assay on the lysates 
from cells normally expressing aS and overexpressing the protein 
and its disease associated mutants. Figure 4(ii) shows the calculated 
initial rates form the experiment. There is a significant increase in 
ferrireductase activity in all the conditions using lysates from cells 
overexpressing aS when compared to lysates from cells normally 
expressing the protein. There was also a significant increase in 
activity in the lysates from cells overexpressing the E46K mutant. 
This suggests that this disease mutant behaves differently to 
normal aS with respect to its enzymatic activity in cells. 
In order to verify that increased cellular ferrireductase activity 
resulted in an increase in reduced iron in cells overexpressing aS 
or its mutants, the levels of ratio of Fe(II) total cellular Fe was 
determined for the stable cell lines using a commercial kit. The 
ratio of Fe(II) to total Fe is shown in Figure 5. As can be seen, 
overexpression of aS resulted in a significant increase in the 
proportion of Fe(II) present in the cells (Student’s t test p,0.05). 
The three mutants of aS also showed significant increases but 
there was no significant difference between any of the mutants and 
wild-type aS. In contrast bS overexpression caused a small but 
significant decrease in the levels of Fe(II). This result indicates that 
the increase in Fe(II) is the result of overexpression of a protein 
with ferrireductase activity. 
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Figure 2. Kinetic plots of the ferrireductase activity of aS at 256C. (i) Ferrozine calibration curve for standards of Fe (II) sulphate monitored at 
562 nm. (ii) The change in absorbance for formation of ferrozine – Fe (II) complex at 562 nm for aS with either 20 mM or 30 mM Fe (III) and controls 
missing either protein, copper or NADH. (iii) Initial rates of activity dependent on substrate concentration. (iv) Double reciprocal plot for the 
calculation of Vmax and Km. 
doi:10.1371/journal.pone.0015814.g002 
Table 1. Comparison of the kinetic parameters for the 
ferrireductase activity of aS and its disease associated 
mutants. 
Mutant Vmax (nmols/min/mg) Km (mM) 
Wildtype 2.72 23 
E46K 2.52 23 
A30P 2.37 19 
A53T 2.62 25 
Assays recorded at 562 nm and 25uC. 
doi:10.1371/journal.pone.0015814.t001 
Discussion 
While the association of aS with a number of diseases has resulted 
in the expression ‘‘synucleinopathies’’ to describe them, the exact 
role of this protein in disease pathogenesis is poorly understood[19]. 
A potential avenue of investigation to identify the mechanism would 
be to identify the function of the protein and then establish how this 
activity is lost or altered in diseases such as Parkinson’s disease. 
There have been a number of suggestions about the possible 
function of aS but none have been conclusively accepted[20]. The 
loss of dopaminergic neurons in Parkinson’s disease has lead to some 
efforts in linking aS to some aspect of dopamine metabolism such as 
vesicular release[21]. The data presented here represents the first 
suggestion of an enzymatic activity for aS that could be of relevance 
for dopaminergic cells. This function also takes into account the 
metal binding capacity of the protein. 
While analysis of copper binding to aS has been relatively 
extensive[4,22,23,24,25,26,27], there has been little consideration 
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Figure 3. Comparison of the ferrireductase activity of the disease associated aS mutants. 
doi:10.1371/journal.pone.0015814.g003 
of iron in this regard[5]. Our findings not only show that aS can free copper. Also, MOPS is a buffer with significantly low 
bind iron but demonstrate that this may be important for the interference with thermodynamic equilibria ensuring that our 
normal activity of the protein. Differences in the affinity values measurements are related only to metal-protein binding events. A 
report by us when compared to others in the literature probably single copper binding site has been reported by others using ITC 
reflect methodological differences. In particular we show a single and our data confirms their findings. In relation to iron our 
copper binding site while others report two sites[4]. The use of experiments were performed under conditions that resulted in little 
chelators in our studies eliminates non-specific interaction and or no precipitation of Fe and the higher affinity we observe reflects 
maintains copper in a more physiological form than those who use this. 
Figure 4. Cellular Ferrireductase Activity. Ferrireductase activity of lysates from neuronal cells normally or over expressing aS and its disease 
associated mutants. (i) The change in absorbance for formation of ferrozine – Fe (II) complex at 562 nm. (ii) A comparison of the initial rates. 
doi:10.1371/journal.pone.0015814.g004 
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Figure 5. Iron Content of Cells. The levels of Fe(II) as compared to total cellular Fe (Fe(II)+Fe(III) in cell lines were assessed using a commercial 
assay. The cell lines were stably tranfected with either pCDNA, aS, the three aS mutants or bS. As a control the parental SH-SY5Y (SH) cell line was also 
analysed. Shown are the mean and standard error for three individual experiments with triplicate analyses. 
doi:10.1371/journal.pone.0015814.g005 
Our data is the first to show that aS can bind two different metals 
simultaneously. Cu(II) saturate aS was still able to bind Fe(III) with 
little change in affinity. This clearly indicates that the two metals 
occupy different sites on the protein. The majority of data suggest 
that copper binds to the N-terminus of aS while iron binds to the C-
terminus. This finding would also suggest that there is a difference in 
the co-ordination of the metals. Some studies have suggested that aS 
can bind more copper than we have shown with ITC. Under these 
conditions copper binding might prevent iron binding at one or 
more sites. However, as previously suggest, replacement of iron by 
copper, and binding of copper at multiple sites on the protein might 
lead to aggregation of the protein. The potential of copper to 
enhance aS aggregation has been observed. In contrast, our 
suggestion is that both copper and iron can bind to the protein 
under normal physiological conditions and allow it catalyse the 
reduction of Fe(III) to Fe(II), indicative of a ferrireductase. 
The data presented here suggests that aS is able to function as a 
cellular ferrireductase. This ties in well with recent evidence 
showing the protein associated with cell membranes [3]. Most 
cellular ferrireductases are found integral or closely associated to 
the bio-membrane [28]. Also, ferrireductases commonly utilise 
redox cycling of copper atoms to remove electrons from iron and 
thus reduce Fe(III) to Fe(II). The data we present shows kinetics 
that fit well with a simple enzyme following a Michaelis-Menten 
model. The activity requires an electron acceptor such as NADH 
and does not occur in the absence of copper. Significantly, the 
activity was observed with both recombinant protein and in cells 
overexpressing aS. Increased Fe (II) levels in the cell confirm that 
the ferrireductase assay measured a reduction process. 
Our findings on aS activity are possibly important for 
understanding its cellular role. However, a key reason for studying 
aS is its role in diseases such as Parkinson’s Disease. In Parkinson’s 
disease the important change that occurs is the loss of 
dopamingeric neurons. When considering the potential role of a 
ferrireductase in dopaminergic cells then the generation of 
increased levels of Fe(II) may be important. A key enzyme in the 
dopamine pathway is tyrosine hydroxylase (TH) [29], an iron (II) 
dependent hydroxylase responsible for catalyzing the conversion of 
the amino acid L-tyrosine to dihydroxyphenylalanine (L-DOPA). 
Disruption of this pathway would occur if bio available Fe (II) was 
reduced as a result of a reduction of ferrireductase activity. 
Additionally, there is a build up of iron (III) in dopaminergic 
neurons in patients suffering from PD [30]. Clearly, a key 
pathological feature of Lewy body dementia is the aggregation of 
aS. It is reasonable to assume that aggregated protein would lose 
any enzymatic activity and hence have an affect on the ability of 
the cell to produce bio-available iron (II). Alternatively, increased 
expression of aS as occurs in Parkinson’s disease may generate 
excess Fe(II) a metal that can catalyse the Fenton reaction and 
generate excess reactive oxygen species which may result in 
apoptosis. While these considerations are highly speculative, it 
does clearly indicate potential mechanisms where by altering 
ferrireductase activity could have a significant impact on the 
survival of dopaminergic neurons. 
aS mutants identified from inherited forms of Parkinson’s 
disease were also studied for their impact on Ferriductase activity 
and iron reduction. There was little evidence that these point 
mutations had any significant effect on this activity. This does not 
preclude the possibility that alterations in ferrireductase activity 
could be important for dopaminergic neuron survival. Partients 
with inherited forms of Parkinson’s disease live a significant part of 
their lives without developing symptoms but have an earlier onset 
of symptoms than seen in sporadic. Therefore it is likely that these 
mutations have their impact in concert with age dependent 
changes. Thus a gross alteration of protein function is unlikely and 
has been confirmed by these findings. 
In summary we have identified aS as a cellular ferrireductase. 
This provides the first finding of a function for this protein via 
direct observation rather than inference. Given the importance of 
maintaining Fe(II) levels in dopaminergic cells, this activity is likely 
to be of considerable importance to understanding the changes 
that occur in dopaminergic cells leading to their selective loss in 
Parkinson’s disease. 
Methods 
All reagents were purchased from Sigma unless otherwise 
stated. 
Recombinant Protein 
aS and bS were produced as previously described [31] with the 
exception that the ammonium sulphate precipitation step was 
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omitted. Additionally, purified protein was dialysed against MilliQ 
filtered water to a 1,000,000 times. Site directed mutagenesis was 
employed to create the disease associated mutants A30P, E46K 
and A53T of aS as previously described [16] using primers 
produced by MWG, Germany. 
Cell Culture 
SH-SY5Y (human neuroblastoma) cells were cultured in 50% 
(v/v) Dulbecco’s Modified Eagle Media and 50% (v/v) Ham’s F­
12 supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/ 
ml penicillin, 100 mg/ml streptomycin and 2 mM glutamine. All 
the media and reagents were obtained from Biowhittaker Lonza. 
Growth conditions were maintained at 37uC and 5% CO2 in a 
humidified incubator. 
Transfections 
Wildtype bS, aS and its disease associated mutants were 
subcloned into pcDNA plasmid transfected using FuGene 6 
transfection reagent (Roche applied science). For stable transfec­
tions, 6-well plates were used and cells were plated at 50% 
confluency the day before the transfection. To perform the 
transfection 50 ml of serum free media was transferred into a 
micro-centrifuge tube; 3 ml of the FuGene 6 reagent was then 
added directly to this and mixed by gentle flicking. The mixture 
was incubated for 5 minutes at room temperature. For each cell 
line, 1 mg of DNA was then added to the mixture, mixed as before, 
and incubated at room temperature for 15 minutes. After this the 
transfection mixture was added to the cells, the 6-well plate swirled 
and returned to the incubator overnight. Cells were selected with 
400 mg/ml G418 sulfate (Calbiochem) 24 hours after transfection, 
and maintained in 100 mg/ml to keep the plasmid in the cells. 
References 
1.	 Burke RE (2004) Recent advances in research on Parkinson disease: synuclein 
and parkin. Neurologist 10: 75–81. 
2.	 Beyer K, Domingo-Sabat M, Ariza A (2009) Molecular pathology of Lewy body 
diseases. Int J Mol Sci 10: 724–745. 
3.	 Beyer K (2007) Mechanistic aspects of Parkinson’s disease: alpha-synuclein and 
the biomembrane. Cell Biochem Biophys 47: 285–299. 
4.	 Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, et al. (2005) 
Structural characterization of copper(II) binding to alpha-synuclein: Insights into 
the bioinorganic chemistry of Parkinson’s disease. Proc Natl Acad Sci U S A 
102: 4294–4299. 
5.	 Bharathi, Rao KS (2007) Thermodynamics imprinting reveals differential 
binding of metals to alpha-synuclein: relevance to Parkinson’s disease. Biochem 
Biophys Res Commun 359: 115–120. 
6.	 Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, et al. (2006) 
Interaction of alpha-synuclein with divalent metal ions reveals key differences: a 
link between structure, binding specificity and fibrillation enhancement. J Am 
Chem Soc 128: 9893–9901. 
7.	 Paik SR, Shin HJ, Lee JH, Chang CS, Kim J (1999) Copper(II)-induced self-
oligomerization of alpha-synuclein. Biochemical Journal 340: 821–828. 
8.	 Lee EN, Lee SY, Lee D, Kim J, Paik SR (2003) Lipid interaction of alpha­
synuclein during the metal-catalyzed oxidation in the presence of Cu2+ and 
H2O2. Journal of Neurochemistry 84: 1128–1142. 
9.	 Binolfi A, Lamberto GR, Duran R, Quintanar L, Bertoncini CW, et al. (2008) 
Site-specific interactions of Cu(II) with alpha and beta-synuclein: Bridging the 
molecular gap between metal binding and aggregation. Journal of the American 
Chemical Society 130: 11801–11812. 
10.	 Yu S, Ueda K, Chan P (2005) Alpha-synuclein and dopamine metabolism. Mol 
Neurobiol 31: 243–254. 
11.	 Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, et al. (2002) A role for alpha­
synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090–3099. 
12.	 Yu S, Zuo X, Li Y, Zhang C, Zhou M, et al. (2004) Inhibition of tyrosine 
hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal 
cells. Neurosci Lett 367: 34–39. 
13.	 Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, et al. (2000) 
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal 
dopamine system. Neuron 25: 239–252. 
Isothermal Titration Calorimetry 
ITC was carried out as previously described [16]. Various 
concentrations of protein were titrated with Cu (II): Glycine in a 
1:2 ratio to a final molar ratio of 1: 5. All solutions were buffered in 
50 mM MOPS (3-(N-Morpholino)propanesulfonic acid) pH 7. 
For analysis of Fe(III) binding, aS was prepared at 250 mM and 
titrated with iron citrated 12.5 mM. Analysis of Fe(III) binding to 
copper saturated aS was also performed. In this case the aS was 
incubated with two molar equivalents of CuSO4 prior to ITC 
experiments. 
Ferrireductase Assay 
Protein solutions of standardised cell lystates or to a final 
concentration of 100 mM recombinant protein were mixed with 
final concentrations of 100 mM ferrozine ((3-(2-pyridyl)-5,6­
bis(phenyl sulfonic acid)-1,2,4-triazine), 50 mM NADH, 100 mM 
MOPS pH 7. Protein had been exposed to 4 equivalents of copper 
(II) sulphate and allowed to equilibrate. The reaction was started 
by the addition of iron (III) citrate to final concentrations between 
1 mM and 100 mM to a final reaction volume of 100 mL. Reactions 
were carried out in 96 well plates and monitored at 562 nm in a 
BMG flurostar. All conditions wee repeated at least 8 times. 
Iron Assay 
Levels of Fe(II) and total Fe were analysed in cell lines using the 
kit from Abcam and following the manufacturer’s instructions. 
Cells were harvested from a confluent T75 for each analysis. 
Author Contributions 
Conceived and designed the experiments: PD DRB. Performed the 
experiments: PD DM DRB. Analyzed the data: PD DM DRB. 
Contributed reagents/materials/analysis tools: DRB. Wrote the paper: 
PD DRB. 
14.	 Kienzl E, Jellinger K, Stachelberger H, Linert W (1999) Iron as catalyst for 
oxidative stress in the pathogenesis of Parkinson’s disease? Life Sciences 65: 
1973–1976. 
15.	 Charkoudian LK, Franz KJ (2006) Fe(III)-coordination properties of neurome­
lanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic 
acid. Inorganic Chemistry 45: 3657–3664. 
16.	 Davies P, Marken F, Salter S, Brown DR (2009) Thermodynamic and 
voltammetric characterization of the metal binding to the prion protein: insights 
into pH dependence and redox chemistry. Biochemistry 48: 2610–2619. 
17.	 Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R (2004) 
Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. 
Anal Biochem 331: 370–375. 
18.	 Galvin JE, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and 
pathological implications. Arch Neurol 58: 186–190. 
19.	 Goedert M, Spillantini MG (1998) Lewy body diseases and multiple system 
atrophy as alpha-synucleinopathies. Mol Psychiatry 3: 462–465. 
20.	 Uversky VN (2008) Alpha-synuclein misfolding and neurodegenerative diseases. 
Curr Protein Pept Sci 9: 507–540. 
21.	 Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from alpha­
synuclein mutations may contribute to the pathogenesis of Parkinson’s disease. 
Hum Mol Genet 11: 2395–2407. 
22.	 Binolfi A, Lamberto GR, Duran R, Quintanar L, Bertoncini CW, et al. (2008) 
Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the 
molecular gap between metal binding and aggregation. J Am Chem Soc 130: 
11801–11812. 
23.	 Brown DR (2009) Metal binding to alpha-synuclein peptides and its contribution 
to toxicity. Biochem Biophys Res Commun 380: 377–381. 
24.	 Drew SC, Leong SL, Pham CL, Tew DJ, Masters CL, et al. (2008) Cu2+ 
binding modes of recombinant alpha-synuclein–insights from EPR spectroscopy. 
J Am Chem Soc 130: 7766–7773. 
25.	 Lee JC, Gray HB, Winkler JR (2008) Copper(II) binding to alpha-synuclein, the 
Parkinson’s protein. J Am Chem Soc 130: 6898–6899. 
26.	 Sung YH, Rospigliosi C, Eliezer D (2006) NMR mapping of copper binding sites 
in alpha-synuclein. Biochim Biophys Acta 1764: 5–12. 
27.	 Hong L, Simon JD (2009) Binding of Cu(II) to human alpha-synucleins: 
comparison of wild type and the point mutations associated with the familial 
Parkinson’s disease. J Phys Chem B 113: 9551–9561. 
PLoS ONE | www.plosone.org	 6 January 2011 | Volume 6 | Issue 1 | e15814 
Synuclein and Iron Reduction 
28.	 Simovich MJ, Conrad ME, Umbreit JN, Moore EG, Hainsworth LN, et al. 30. Wolozin B, Golts N (2002) Iron and Parkinson’s disease. Neuroscientist 8: 
(2002) Cellular location of proteins related to iron absorption and transport. 22–32.

Am J Hematol 69: 164–170. 31. Wright JA, Wang X, Brown DR (2009) Unique copper-induced oligomers

29.	 Masserano JM, Weiner N (1983) Tyrosine hydroxylase regulation in the central mediate alpha-synuclein toxicity. Faseb J 23: 2384–2393. 
nervous system. Mol Cell Biochem 53-54: 129–152. 
PLoS ONE | www.plosone.org	 7 January 2011 | Volume 6 | Issue 1 | e15814 
